Papers
2
Total Citations
79
H-Index
2
About
Jeffrey Elbich is a leading figure in urologic oncology, specializing in the comparative effectiveness of minimally invasive treatments for renal masses. His research centers on optimizing outcomes for complex kidney cancer cases, particularly through the rigorous comparison of robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA). Elbich’s major contributions include landmark multicenter studies that provide critical, long-term data on these competing approaches. His 2022 trifecta analysis, cited 40 times, demonstrated that for completely endophytic renal masses—a notoriously challenging tumor location—PTA offers comparable oncologic control with lower perioperative morbidity than RAPN over a minimum three-year follow-up. In a second highly cited work (39 citations), he extended this analysis to patients with a solitary kidney, showing that PTA achieves superior trifecta outcomes (a composite of complication-free, cancer-free, and renal function preservation) in this vulnerable population. These findings have directly influenced clinical guidelines, offering surgeons and patients evidence-based options for nephron-sparing treatment. Elbich’s work is distinguished by its multicenter design, rigorous statistical methodology, and focus on patient-centered endpoints, establishing him as a key voice in the ongoing evolution of renal cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2